Porang Glucomannan Supplementation Improves Lipid Profile in Metabolic Syndrome Induced Rats
Keywords:Glucomannan, Lipid Profile, Metabolic Syndrome, Porang
AbstractBackground: Porang glucomanan has been shown to have a potential properties for the prevention of Metabolic Syndrome (MetS). This study aimed to confirm that porang glucomannan supplementation can improve lipid profile in metabolic syndrome induced rats.Methods: Thirty male Sprague-Dawley rats were randomly divided into 5 groups consisting a contol group standard diet (Normal); Metabolic Syndrome group (SM), metabolic syndrome group + 25mg/200gBW Porang Glucomannan (GMP25), metabolic syndrome group + 50mg/200gBW Porang Glucomannan (GMP50), and metabolic syndrome group + 100mg/200gBW Porang Glucomannan (GMP100). The lipid profile before and after induction with high-fat and high-carbohydrate diet, and after 28 days of porang treatment were evaluated. Data were analyzed using One Way Anova followed by LSD post hoc test. Results: GMP100 rats showed the highest reversal of diet-induced changes, with decreased total cholesterol (TC), triglycerides (TG), and LDL, and also increased HDL level. The mean levels of TC, TG, and LDL in GMP100, GMP50 and GMP25 was significantly lower than those of in MS (p = 0.000), and was significantly higher than those of normal (p = 0.000). While the levels of HDL in GMP 100, GMP50, and GMP25 was significantly higher than those of MS (p = 0.000), but significantly lower than those of normal (p = 0.000). Conclusion: Porang glucomannan supplementation improve lipid profile in metabolic syndrome diet rats, with best dose at 100 mg/200 gBW.
Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; and International association for the study of obesity. Circulation. 2009; 120(16):1640–5. DOI: 10.1161/CIRCULATIONAHA.109.192644. Crossref.
Alberti KG, Zimmet P, Shaw J. Metabolic SyndromeA new world"wide definition. A consensus statement from the international diabetes federation. Diabetic Medicine. 2006; 23(5):469–80. DOI: 10.1111/j.14645491.2006.01858.x. Crossref.
What is metabolic syndrome. American Heart Association; 2015. p. 1–2.
Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. Jama. 2015; 313(19):1973–4. DOI: 10.1001/jama.2015.4260. Crossref.
Okafor C. The metabolic syndrome in Africa: Current trends. Indian J Endocrinol Metab. 2012; 16(1):56.DOI: 10.4103/2230-8210.91191. Crossref.
Balkau B, Charles MA, Drivsholm T, Wareham N, Yud- kin JS, Morris R, et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab. 2002; 28:364–76. DOI: DM-11-2002-28-5-1262-3636-101019-ART3.
Nestel P, Lyu Phd R, Huey W, Sheu -Hernig, Md WN, Saito I, et al. Metabolic syndrome: Recent prevalence in East and Southeast Asian populations. Asia Pac J Clin Nutr. 2007; 16(2):362–7.PMid:17468095
Goodarzi MT, Mohammadian M, Borzouei S, Hassanzadeh T. Association between Plasma cholesteryl ester transfer protein activity and lipid profiles in metabolic syndrome in an Iranian population. Int Res J Biol Sci. 2014; 3(4):2278–3202.ISSN: 2278-3202.
Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S, et al. Relationships between lipid profiles and metabolic syndrome, insulin resistance and serum high molecular adiponectin in Japanese community-dwelling adults. Lipids Health Dis. 2011; 10(1):79. Available from: http://www.lipidworld.com/content/10/1/79. Crossref. PMid:21586120 PMCid:PMC3118370
Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. Diabet Med. 1999; 16(5):442–3. DOI: 10.1046/j.14645491.1999.00059.x. Crossref.
Galisteo M, Duarte J, Zarzuelo A. Effects of dietary fibers on disturbances clustered in the metabolic syndrome. J Nutr Biochem. 2008; 19(2):71–84. DOI: 10.1016/j.jnutbio.2007.02.009. Crossref.
Connolly ML, Lovegrove JA, Tuohy KM. Konjac Glucomannan hydrolysate beneficially modulates bacterial composition and activity within the faecal microbiota. J Funct Foods. 2010; 2(3):219–24. DOI: 10.1016/j.jff.2010.05.001.Crossref.
Safitri AH, Meryandini A. Enzymatic hydrolysis of porang by Streptomyces violascens BF 3.10 mannanase for the production of mannooligosaccharides. Med Pet. 2014; 37(3):190–7. DOI: 10.5398/ medpet.2014.37.3.190. Crossref.
Gallaher CM, Munion J, Hesslink R, Wise J, Gallaher DD. Cholesterol reduction by glucomannan and chitosan is mediated by changes in cholesterol absorption and bile acid and fat excretion in rats. Am J Clin Nutr. 2000; 130(11):2753–9.Crossref.
Jones PJH. Dietary agents that target gastrointestinal and hepatic handling of bile acids and cholesterol. J Clin Lipidol. 2008; 2(2):S4–10. DOI: 10.1016/j.jacl.2008.01.005. Crossref.
Koswara S. Teknologi pengolahan umbi"umbian bagian 2: Pengolahan umbi porang. bogor. Research and Community Service Institution IPB; 2013.Available from: http://seafast.ipb.ac.id
Panchal SK, Poudyal H, Iyer A, Nazer R, Alam MA, Diwan V, et al. High-carbohydrate, high-fat diet– induced metabolic syndrome and cardiovascular remodeling in rats: Erratum. J Cardiovasc Pharmacol. 2011; 57(5):610. DOI: 10.1097/ FJC.0b013e3181feb90a.Crossref.
Sánchez I, Reynoso-Camacho R, Salgado LM. The diet-induced metabolic syndrome is accompanied by whole-genome epigenetic changes. Genes Nutr.2015; 10(4):21. DOI: 10.1007/s12263-015-0471-5.Crossref.
Sood N, Baker WL, Coleman CI. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: Systematic review and meta-analysis. Am J Clin Nutr. 2008; 88(4):1167–75.PMid:18842808
Chen HL, Sheu WHH, Tai TS, Liaw YP, Chen YC.Konjac supplement alleviated hypercholesterolemia and hyperglycemia in type 2 diabetic subjects- A randomized double-blind trial. J Am Coll Nutr. 2003; 22(1):36–42. DOI: 10.1080/07315724.2003.10719273.Crossref.
Arvill A, Bodin L. Effect of short-term ingestion of konjac glucomannan on serum cholesterol in healthy men. Am J Clin Nutr. 1995; 61(3):585–9.Available from: http://www.ncbi.nlm.nih.gov/ pubmed/7872224. Crossref. PMid:7872224
Cheang KU, Chen CM, Chen CO, Liang FY, Shih CK, Li SC. Effects of glucomannan noodle on diabetes risk factors in patients with metabolic syndrome: A double-blinded, randomized crossover controlled trial. J Food Nutr Res. 2017; 5(8):622–8. DOI: 10.12691/jfnr-5-8-13.
Zalewski BM, Chmielewska A, Szajewska H. The effect of glucomannan on body weight in overweightoor obese children and adults: A systematic review of randomized controlled trials. Nutrition. 2015; 31:437–442.e2. DOI: 10.1016/j.nut.2014.09.004.Crossref.
Jenkins DJ, Jenkins AL, Wolever TM, Vuksan V, Rao A V, Thompson LU, et al. Low glycemic index: Lente carbohydrates and physiological effects of altered food frequency. Am J Clin Nutr. 1994; 59(3 Suppl):706S–9S. Crossref. PMid:8116554
Yanuriati A, Marseno DW, Rochmadi, Harmayani E.Characteristics of glucomannan isolated from fresh tuber of porang (Amorphophallus Muelleri Blume).Carbohydr Polym. 2017; 156:56–63. DOI 10.1016/j.carbpol.2016.08.080. Crossref.
Al-Ghazzewi FH, Khanna S, Tester RF, Piggott J. The potential use of hydrolysed konjac glucomannan as a prebiotic. J Sci Food Agric. 2007; 87(9):1758–66.DOI: 10.1002/jsfa.2919. Crossref.
Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications part 1 : diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15(7):539–53.Crossref.
Mccarty MF, Dinicolantonio JJ. Prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1. Open Heart. 2015; 2(1):e000205. DOI: 10.1136/openhrt-2014-000205.Crossref.
Patel VJ, Joharapurkar AA, Shah GB JM. Effect of GLP-1 based therapies on diabetic dyslipidemia. Curr Diabetes Rev. 2014; 10(4):238–50. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24998439.Crossref. PMid:24998439
Farr S, Taher J, Adeli K. Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states. Cardiovascular and Haematological Disorders-Drug Targets (Formerly Current Drug Targets-Cardiovascular and Hematological Disorders). 2014; 14(2):126–36.Crossref.